TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00770718

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Activated Factor VII (rFVIIa)
Description: Five patients who meet the selection criteria will be administered an intravenous dose of rFVIIa 1mg upon arrival. INR will be drawn at 20 minutes post-rFVIIa administration. If normalized (≤1.3), then repeat INR with be drawn every 2 hours thereafter for 6 hours total, and again at 24 hours after initial administration. If at any time, the INR is \>1.3, then rFVIIa 1mg will be readministered and the INR will again be checked 20 minutes after administration and every 2 hours for 6 hours total and again at 24 hours post-administration. This may be repeated until a total dose of 80mcg/kg has been given.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prothrombin Complex Concentrate
Description: 5 patients will receive PCC based on ideal body weight. Each patient will receive 30 i.u./kg ideal body weight as is rounded to the nearest dispensed vial size. Vials are dispensed as 5mL (500 i.u.), 10mL (1000 i.u.), or 10mL (1500i.u.). INR will be drawn at 20 minutes post-administration and, if normalized (≤1.3), 2 hours post-administration and every 2 hours for 6 hours total. The INR will also be checked 24 hours post-administration. If at any time, the INR is \>1.3, then PCC will be readministered at the same dose and the INR will again be checked 20 minutes after administration and every 2 hours for 6 hours total and again at 24 hours post-administration. A maximum total of 60 iu/kg can be administered.
Study: NCT03851692

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous Cannulation (iv placement)
Description: The aim of our study is to determine whether one should make intravenous attempts placement during the early induction period (at 60seconds) or lately (90 or 120 s) and waiting until the child receives additional sevoflurane inhalation anesthesia.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous Cannulation (iv placement)
Description: The aim of our study is to determine whether one should make intravenous attempts placement during the early induction period (at 60seconds) or lately (90 or 120 s) and waiting until the child receives additional sevoflurane inhalation anesthesia.
Study: NCT00770718

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fresh Frozen Plasma
Description: Five patients will receive transfusions of FFP to normalize INR. If the initial INR is between 2-4, then 2 units of FFP (Round 1) will be administered emergently. If the initial INR is \>4, then 4 units of FFP will be administered (Round 1). The INR will be checked after each round of FFP infusion completed. Once INR ≤1.3, then the INR will be again checked every 2 hours after normalization for 6 hours total and then 24 hours post-initial infusion. If the INR should ever return to \>1.3, then repeat infusions of FFP will begin as outlined above and the INR will be checked serially as defined above.
Study: NCT00737529

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide
Description: 25mg oral capsules continuous days 1-21 each of a 28 day cycle
Study: NCT01717534

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: heat-treated lactobacilli or placebo
Description: Daily supplement of sachet with 1 g of powder over a 5 months period.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: heat-treated lactobacilli or placebo
Description: Daily supplement of sachet with 1 g of powder over a 5 months period.
Study: NCT04077333

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Minimal Invasive surfactant administration
Description: Participants enrolled spontaneously breathing preterm infants born between 26.1 and 31.9 weeks' gestational age with signs of respiratory distress syndrome. Preterm infants of the MISA (Minimal invasive surfactant administration) group were assigned to receive surfactant (Calf pulmonary surfactant, Double-Crane Pharmaceutical Co., China) via a 5Fr nasogastric tube with an ophthalmic surgery straight forceps during CPAP/NIPPV-assisted spontaneous breathing.
Study: NCT01193686

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Peer Visitation
Description: Trained Volunteers will visit OEF/OIF Veterans with Polytrauma Injuries to provide support.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Peer Visitation
Description: Trained Volunteers will visit OEF/OIF Veterans with Polytrauma Injuries to provide support.
Study: NCT03325764

Intervention type: OTHER
Group type: OTHER
Intervention: functional assessment
Description: assessment of functional capacity, habitual physical, cardiorespiratory fitness, muscle power and postural stability and gait parameters
Study: NCT02515513

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Muscle Tissue Biopsy Sample
Description: During surgical resection, to enter the abdominal cavity, anterior muscle groups such as the rectus abdominous muscle. This group of muscle is divided. During division, muscle fibers are released from fascial group and discarded off the operative field. This will be the target for specimen collection.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Muscle Tissue Biopsy Sample
Description: During surgical resection, to enter the abdominal cavity, anterior muscle groups such as the rectus abdominous muscle. This group of muscle is divided. During division, muscle fibers are released from fascial group and discarded off the operative field. This will be the target for specimen collection.
Study: NCT00432809

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Gastric bypass
Description: Roux-en-Y gastric bypass

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sleeve Gastrectomy
Description: Laparoscopic sleeve gastrectomy
Study: NCT00420030

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abciximab
Description: Abciximab - IIb/IIIa GP inhibitor, dosage - bolus + continuous infusion

Intervention type: DRUG
Group type: OTHER
Intervention: Abciximab
Description: Abciximab - IIb/IIIa GP inhibitor, dosage - bolus + continuous infusion
Study: NCT01147809

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eltrombopag olamine
Description: thrombopoietin receptor agonist

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets with no active pharmaceutical ingredient
Study: NCT03860506

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PSI-697

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02910427

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Regular salt
Description: Participants eat a regular salt diet.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Potassium-enriched salt
Description: Participants eat a potassium-enriched salt diet.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Potassium and magnesium-enriched salt
Description: Participants eat a potassium and magnesium-enriched salt diet.
Study: NCT03757039

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Multifocal soft contact lenses
Description: Commercially available contact lenses

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Progressive addition lens spectacles
Description: Per subject's habitual prescription
Study: NCT03284190

Intervention type: PROCEDURE
Intervention: Surgery
Description: Surgery

Intervention type: PROCEDURE
Intervention: Surgery
Description: Surgery

Intervention type: PROCEDURE
Intervention: Surgery
Description: Surgery

Intervention type: PROCEDURE
Intervention: Surgery
Description: Surgery

Intervention type: PROCEDURE
Intervention: Surgery
Description: Surgery

Intervention type: PROCEDURE
Intervention: Surgery
Description: Surgery
Study: NCT03896347

Intervention type: OTHER
Intervention: Bone Morphogenetic Protein
Description: Bone Morphogenetic Protein

Intervention type: OTHER
Intervention: Bone Morphogenetic Protein
Description: Bone Morphogenetic Protein

Intervention type: OTHER
Intervention: Bone Morphogenetic Protein
Description: Bone Morphogenetic Protein
Study: NCT01673152

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oligofructose
Description: Dosing: children aged 7 to 12 years: 8g/day, children aged 12 to18 years: 15g/day Duration: 12 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin
Description: Dosing: children aged 7 to 12 years: 4g/day, children aged 12 to18 years: 6g/day, Duration: 12 weeks
Study: NCT03284190

Intervention type: PROCEDURE
Intervention: Surgery
Description: Surgery

Intervention type: PROCEDURE
Intervention: Surgery
Description: Surgery

Intervention type: PROCEDURE
Intervention: Surgery
Description: Surgery

Intervention type: PROCEDURE
Intervention: Surgery
Description: Surgery
Study: NCT01126346

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HIPEC Orientation
Description: Introduction to SRB (survivorship resource book); Clinic Tour; Lunch with Question and Answer Session

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Consultation with Survivorship Navigator
Description: Weekly psychosocial support via phone from Survivorship Navigator for 3 weeks prior to HIPEC; Inpatient consults occurring 3 to 4 days post-HIPEC and biweekly for 2 weeks and weekly until hospital discharge; Post-Hospital Discharge consults via phone twice per month for one month

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Questionnaires Completed at 4 time points: T1 pre-HIPEC orientation, T2 with in 1 week of orientation, T3 1 month post HIPEC and T4 3 months post HIPEC. Questionnaires include Utility of SRB, Medical Outcomes Study Health Survey, Short Form (SF-12), Center for Epidemiologic Studies-Depression Scale (CES-D), The Brief Illness Perception Questionnaire, The Distress Thermometer, The State-Trait Anxiety Inventory (STAI)
Study: NCT04636905

Intervention type: OTHER
Intervention: Questionnaires
Description: Participants will be asked to complete a series of questionnaires assessing quality of life and other general health outcomes
Study: NCT02209766

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D5884
Description: 1st cohort: Dose 1(2g) D5884(n=6) in Japanese 2nd cohort: Dose 2(4g) D5884(n=6) in Japanese 3rd cohort: Dose 2(4g) D5884(n=6) in Caucasian
Study: NCT02787486

Intervention type: OTHER
Intervention: Blood sampling for Laboratory Developed Test (LDT) analysis
Description: Each enrolled subject, either in the first or second trimester, will donate up to 50 mL (just over 3 tablespoons) of whole blood for development of the LDT

Intervention type: OTHER
Intervention: Blood sampling for Laboratory Developed Test (LDT) analysis
Description: Each enrolled subject, either in the first or second trimester, will donate up to 50 mL (just over 3 tablespoons) of whole blood for development of the LDT
Study: NCT01932879

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blackberry
Description: Participants will be fed a higher fat, typical American diet for two 1-week periods. Participants must consume only and all food provided during the intervention periods.

Intervention type: OTHER
Group type: OTHER
Intervention: Jello
Study: NCT02335671

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intra-operative Magnetic Resonance Imaging (MRI)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mass Spectrometer Analysis of Tissue Sample
Description: Analysis of Tissue Sample
Study: NCT05542745

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: palatal and buccal retraction
Description: comparison

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: palatal and buccal retraction
Description: comparison
Study: NCT02066987

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Implementation intention
Description: It may be helpful for you to plan when and where you will brush your teeth each day over the next month. Please write below when, where, and after what activity you will brush your teeth (e.g., at 8.00 a.m. and 9.00 p.m. in the bathroom after eating breakfast/dinner). Because you should brush your teeth twice a day, please make two plans.~If it is _____ (WHEN) at or in _______ (WHERE) before/after ______ (ACTIVITY), then I will brush my teeth! If it is _____ (WHEN) at or in _______ (WHERE) before/after ______ (ACTIVITY), then I will brush my teeth!

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Action planning
Description: It may be helpful for you to plan when and where you will brush your teeth each day over the next month. Please write below when, where, and after what activity you will brush your teeth (e.g., at 8.00 a.m. and 9.00 p.m. in the bathroom after eating breakfast/dinner). Because you should brush your teeth twice a day, please make two plans.~I will brush my teeth at ___(WHEN) at or in ____(WHERE) before/after ___ (ACTIVITY).~I will brush my teeth at ___(WHEN) at or in ____(WHERE) before/after ___ (ACTIVITY).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: active control group
Description: Participants in the active control group will receive an educational pamphlet containing what it is dental brushing, why it is done, and how it is done.
Study: NCT03149367

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: levator muscle resection with fixed sutures technique
Description: The levator muscle is approached through skin incision and the muscle shortened and sutured directly to the tarsus then the skin crease reformed with interrupted sutures which pick up the underlying levator muscle

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Levator muscle resection with adjustable sutures technique
Description: The adjustable sutures technique in which the sutures passes through the levator muscle into the tarsal plate and out through the skin edge .the skin crease is formed separately so that adjusting the suture doesn't open the wound, the suture can be adjusted according to the result up to 4 days post operative.
Study: NCT03769376

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bio-Oss®
Description: Bio-Oss® xenograft bone material will be placed into the socket following tooth extraction.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Salvin-Oss®
Description: Salvin-Oss® xenograft bone material will be placed into the socket following tooth extraction.
Study: NCT04486898

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music group
Description: Music group will be given music intervention or listen to music for 30 minutes ,3 times a week for the period of 5 week duration. Music will be selected as per participant's preference
Study: NCT00296608

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional surgery

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiation therapy
Study: NCT03149848

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabotegravir
Description: It will be available as a white aquarius film coated tablet for oral administration. CAB Tablet is composed of GSK1265744B (micronized) lactose monohydrate, microcrystalline cellulose, hypromellose, sodium starch glycolate, magnesium stearate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabotegravir
Description: It will be available as a white aquarius film coated tablet for oral administration. CAB Tablet is composed of GSK1265744B (micronized) lactose monohydrate, microcrystalline cellulose, hypromellose, sodium starch glycolate, magnesium stearate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifabutin
Description: It will be available as an opaque red-brown hard gelatin capsules containing 150 mg of rifabutin for oral administration. These capsules are composed of rifabutin, microcrystalline cellulose, sodium lauryl sulphate, magnesium stearate, and silica gel
Study: NCT01244490

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Extended-release Guanfacine Hydrochloride
Description: Tablet, once daily, optimised dose (1mg to 7mg based on age and weight), 6-week maintenance duration on optimised dose.

Intervention type: DRUG
Group type: OTHER
Intervention: Atomoxetine Hydrochloride
Description: Capsule, once daily, optimised dose (10mg to 100mg based on weight), 8-9-weeks maintenance duration on optimised dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: Placebo
Study: NCT02209766

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1. st cohort: Dose 1(2g) D5884(n=3) in Japanese~2. nd cohort: Dose 2(4g) D5884(n=3) in Japanese
Study: NCT00507247

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daptomycin
Description: 6mg/kg/day IV for at least 10 days.
Study: NCT00762346

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zometa
Description: zometa 4mg i.v. every 4 weeks for up to 2 years
Study: NCT03411343

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Interscalene Block
Description: Injection with ultrasound guidance of 20mL of levobupivacaine 0.5% with 5 micrograms of epinephrine per mL in the interscalene groove of the brachial plexus.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Costoclavicular Infraclavicular Block
Description: Ultrasound guided brachial plexus block injecting 20mL of 0.5% levobupivacaine with 5 micrograms of epinephrine per mL in between the cords of the brachial plexus at the costoclavicular infraclavicular space.
Study: NCT04381234

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: dialyzer
Description: Asymmetric triacetate dialyzer
Study: NCT01416584

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: methadone contingency
Description: Participants had to enroll in methadone treatment and take daily doses of methadone to gain access to the workplace.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: methadone contingency
Description: Participants had to enroll in methadone treatment and take daily doses of methadone to gain access to the workplace.
Study: NCT04381234

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: dialyzer
Description: Asymmetric triacetate dialyzer

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: hemodialysis with citrate-containing dialysate
Description: acetate-free dialysate

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: predilution hemodiafiltration
Description: predilution hemodiafiltration
Study: NCT01919892

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lithium
Study: NCT01881646

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Positron emission tomography (PET) using [11C]PBR28
Study: NCT00981994

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Decision Support for ARI Management
Description: Use of history and physical examination findings to estimate probability of pneumonia in patients with acute respiratory infections and thereby guide treatment decisions

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Decision Support for ARI Management
Description: Use of history and physical examination findings to estimate probability of pneumonia in patients with acute respiratory infections and thereby guide treatment decisions
Study: NCT00511420

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Cocoa product type 1
Description: 6 doses of 13 grams per day during 4 weeks with a prior stabilization period of 2 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Cocoa product type 2
Description: 6 doses of 13 grams per day during 4 weeks with a prior stabilization period of 2 weeks with cocoa product type 1

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Cocoa product type 3
Description: 6 doses of 13 grams per day during 4 weeks with a prior stabilization period of 2 weeks with cocoa product type 1
Study: NCT01416584

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Methadone & Abstinence Contingency
Description: Participants had to enroll in methadone treatment and take daily doses of methadone to gain access to the workplace and they had to provide opiate and cocaine negative urine samples to maintain the maximum pay.
Study: NCT03696394

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BioCartilage® Micronized Cartilage Matrix
Description: BioCartilage® is a scaffold with Collagen Type II and cartilage matrix elements
Study: NCT00287963

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: topotecan hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vinorelbine tartrate
Study: NCT03289286

Intervention type: OTHER
Group type: OTHER
Intervention: Dedicated and coordinated e-follow-up.
Description: In pre- and post-surgery:~* Completion of questionnaires using an electronic tool,~* Telephone follow-up if necessary between the nurse and the patient.
Study: NCT00007852

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Rituximab at 375 mg/m2 administered approximately one week apart prior to collection of the hematopoietic stem cells. Rituxan at a dose of 375 mg/m2 IV will be given either on the days prior to initiation of the BCNU (days -10 to -7) or on the same day that the BCNU is administered for the BEAM chemotherapy regimen (Day -6). A fourth infusion of Rituxan 375 mg/m2 will be given at 30 day (+/- 20 days) post-transplant. At approximately 6 months post-transplant, if the patients have not had progressive lymphoma, they will receive four weekly doses of Rituxan 375 mg/m2 IV.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carmustine
Description: BCNU 300 mg/M2 IV day -6

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: 100 mg/m2 on days -5 through -2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: 100mg/M2 BID on days -5 through -2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: melphalan
Description: 140 mg/m2 IV on day -1

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: autologous hematopoietic stem cell transplantation
Description: Following the chemotherapy, on day 0 of treatment, the previously stored hematopoietic stem cells will be reinfused via the central venous line